# US 2013/0261099 A1 · Fatty Acid Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261099 A1
- Document ID: US20130261099A1
- Status: Published application
- Kind: A1
- Application number: 13/902,543
- Filed: 2013-05-24
- Published: 2013-10-03
- Earliest claimed: 2009-11-02
- Assignees: Life Technologies Corporation
- Applicants: Life Technologies Corporation
- Inventors: Bruce BRANCHAUD
- Web page: https://patentgrep.com/patent/US20130261099A1

## CPC

- C07D 303/48: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07C 57/03: Monocarboxylic acids
- C07C 205/55: having nitro groups or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C07D 203/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 303/38: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 305/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 331/02: Three-membered rings
- C07D 331/04: Four-membered rings
- C07C 2601/02: with a three-membered ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein.

## Claims

### Claim 1

A compound comprising an unsaturated or polyunsaturated fatty acid or pharmaceutically Formulae:
Wherein:
R1 is H or an electron withdrawing group selected from the group consisting of aldehyde (—COH), acyl (—COR), carbonyl (—CO), carboxylic acid (—COOH), ester (—COOR), halides F, —Br, —I), fluoromethyl (—CFn), allyl fluoride (—CH═CHCH2F), cyano (—CN), sulfoxide (—SOR), sulfonyl (—SO2R), sulfonic acid (—SO3H), 1°, 2° and 3° ammonium (—NR3+), and nitro (—NO2), wherein R is a hydrogen, methyl or C2-C6 alkyl;
R2 when present is H or an electron withdrawing group selected from the group consisting of aldehyde (—COH), acyl (—COR), carbonyl (—CO), carboxylic acid (—COOH), ester (—COOR), halides (—Cl, —F, —Br, —I), fluoromethyl (—CFn), allyl fluoride (—CH═CHCH2F), cyano (—CN), sulfoxide (—SOR), sulfonyl (—SO2R), sulfonic acid (—SO3H), 1°, 2° and 3° ammonium (—NR3+), and nitro (—NO2), wherein R is a hydrogen, methyl or C2-C6 alkyl and the other is —H;
X is a leaving group selected from the group consisting of diazonium salts (—N2+), nonaflates (R—OSO2C4F9), triflates (—OSO2CF3), fluorosulfonates (—OSO2F), tosylates (—OTs), mesylates (—OMs), halides, (—F, —Cl, —Br, —I), conjugate acid of alcohols (—OH2+), acyl chlorides (—R(O)Cl), conjugate acid of an ethers (—OHR′+), nitrates (—ONO2), phosphates (—OPO(OH)2), tetraalkylammonium salts (—NR′3+), esters (—OC(O)R′), acid anhydrides (—C(O)OC(O)R′), ammonium salts (—NH3+), phenoxides (—OAr), alcohols (—OH), carboxylic acids (—C(O)OH), ethers (—OR′), and esters (—C(O)OR′);
each R′ is, independently, selected from the group consisting of hydrogen (—H) or C1 to C6 alkyl, alkenyl, or alkynyl; and
Y is a leaving group within the main chain selected from the group consisting of —O—, NR″—, —S—, —SO—, —SO2—, and —POR″—;
Q is a heteroatom selected from the group consisting of —O—, —S—, —NR′″—, —CR′″2—, and C═CR′″2, wherein R′″ is —H, C1 to C6 alkyl, alkenyl, alkynyl, or aryl;
Z is a ketone, ester, amide, or thioester; and
m and n can, independently, be 1-20;

### Claim 2 (depends on 1)

The compound of claim 1, wherein the unsaturated or polyunsaturated fatty acid comprises an aliphatic chain having 5 to 23 carbons.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the unsaturated or polyunsaturated fatty acid is selected from a glycolipid, a glycerolipid, a phospholipid and a cholesterol ester.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is nitro (—NO2).

### Claim 5 (depends on 1)

The compound of claim 1, wherein the one or more electron withdrawing group is positioned on an alpha carbon of a carbon-carbon double bond of the non-naturally occurring, unsaturated or polyunsaturated fatty acid.

### Claim 6 (depends on 1)

The compound of claim 1, wherein a carbon-carbon double bond associated with R1 is in cis configuration.

### Claim 7 (depends on 1)

The compound of claim 1, wherein a carbon-carbon double bond associated with R1 is in trans configuration.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the unsaturated or polyunsaturated fatty acid comprises two or more conjugated carbon-carbon double bonds.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R1 is at any carbon in the two or more conjugated carbon-carbon double bonds.

### Claim 10 (depends on 1)

The compound of claim 1, wherein at least R1 is positioned at C-9, C-10, C-12, C-13 or a combination thereof.

### Claim 11 (depends on 1)

The compound of claim 1, further comprising one or more non-carbon-carbon linkage selected from an ester linkage, an ether linkage, and a vinyl ether linkage.

### Claim 12 (depends on 1)

The compound of claim 1, further comprising one or more functional group other than an electron withdrawing group positioned at any carbon of the unsaturated or polyunsaturated fatty acid.

### Claim 13 (depends on 1)

The compound of claim 1, further comprising a pharmaceutically acceptable carrier, excipient, or combination thereof.

### Claim 14 (depends on 13)

The compound of claim 13, further comprising one or more of diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, antioxidants, preservatives or combinations thereof.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the unsaturated or polyunsaturated fatty acid or pharmaceutically acceptable salt thereof further comprising a pharmaceutically acceptable carrier or excipient is formulated as a solid, solution, powder, fluid emulsion, fluid suspension, semi-solid, or dry powder.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising an effective amount of an unsaturated or polyunsaturated fatty acid of claim 1 and at least one pharmaceutically acceptable carrier, excipient, or combination thereof.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, further comprising one or more of diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, antioxidants, preservatives or combinations thereof.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is formulated as a solid, solution, powder, fluid emulsion, fluid suspension, semi-, solid, or dry powder.

### Claim 19 (depends on 1)

A method for treating a condition comprising administering to an individual in need of treatment an effective amount of an unsaturated or polyunsaturated fatty acid of claim 1.

### Claim 20 (depends on 17)

The method of claim 17, wherein the condition is selected from arterial stenosis, burns, hypertension, obesity, neurodegenerative disorders, skin disorders, arthritis, autoimmune disease, autoinflammatory disease, lupus, Lyme's disease, gout, sepsis, hyperthermia, ulcers, enterocolitis, osteoporosis, viral or bacterial infections, cytomegalovirus, periodontal disease, glomerulonephritis, sarcoidosis, lung disease, chronic lung injury, respiratory distress, lung inflammation, fibrosis of the lung, asthma, acquired respiratory distress syndrome, tobacco induced lung disease, granuloma formation, fibrosis of the liver, graft vs. host disease, postsurgical inflammation, coronary and peripheral vessel restenosis following angioplasty, stent placement or bypass graft, acute and chronic leukemia, B lymphocyte leukemia, neoplastic diseases, arteriosclerosis, atherosclerosis, myocardial inflammation, psoriasis, immunodeficiency, disseminated intravascular coagulation, systemic sclerosis, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, encephalomyelitis, edema, inflammatory bowel disease, hyper IgE syndrome, cancer metastasis or growth, adoptive immune therapy, reperfusion syndrome, radiation hums, and alopecia.
